









Markets
/
Stocks
/
nasdaq-apm
/

Aptorum Group Ltd

APM

1.780USD

-0.140-7.29%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

9.98MMarket Cap

--P/E TTM



Aptorum Group Ltd

1.780

-0.140-7.29%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

302 / 506

Overall Ranking

570 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

Fairly Valued

The company’s latest PE is -2.27, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.14M shares, decreasing 16.85% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.16.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.45, which is -14.12% below the recent high of -2.11 and -79.06% above the recent low of -4.39.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 302/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.30, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.71 and the support level at 0.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.30

Change

-0.59

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.064

Neutral

RSI(14)

48.765

Neutral

STOCH(KDJ)(9,3,3)

44.783

Sell

ATR(14)

0.157

High Vlolatility

CCI(14)

-8.612

Neutral

Williams %R

63.175

Sell

TRIX(12,20)

0.145

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.862

Sell

MA10

1.837

Sell

MA20

1.977

Sell

MA50

1.731

Buy

MA100

1.351

Buy

MA200

1.195

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

CGY Investments Ltd

533.58K

Jurchen Investment Corp

370.31K

Huen (Ian)

137.66K

Geode Capital Management, L.L.C.

36.95K

-3.76%

Osaic Holdings, Inc.

5.50K

Citi Investment Research (US)

19.00

SBI Securities Co., Ltd.

67.00

-50.37%

L1 Capital Global Opportunities Master Fund Ltd.

-100.00%

XTX Markets LLC

10.04K

Morgan Stanley & Co. LLC

21.16K

+134.60%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.06, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.